Ocular Therapeutix™ to Participate in December Scientific Conferences

November 24, 2026

BEDFORD, Mass., Nov. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in December 2026.

Upcoming Scientific Conferences:

Eyenovate @ FLORetina 2026: December 3, 2026
Florence, Italy

- **Presentation: OTX-TKI: Early Fluid Control and Durability Outcomes in SOL-1**
  Session: The Hunt for a Durable wAMD Treatment
  Presentation Date/Time: Thursday, December 3, 2026, 9:56 – 10:00 AM CET
  Presenter: Darius M. Moshfeghi, MD, FASRS

- **Panel Discussion: The Near and Far Future of Wet AMD Treatment: Durability, New Treatment Pathways, Combined Therapies**
  Session: The Hunt for a Durable wAMD Treatment
  Panel Date/Time: Thursday, December 3, 2026, 10:20 – 10:50 AM CET
  Panelist: Namrata Saroj, OD, Chief Business Officer

- **Presentation: TKIs – Why This Has Us Excited**
  Session: Vascular/Diabetic Retinal Diseases: New Associations and Treatments
  Presentation Date/Time: Thursday, December 3, 2026, 11:39 – 11:43 AM CET
  Presenter: Peter K. Kaiser, MD, Chief Development Officer

- **Panel Discussion: From Controlling Neovascularization to Restoring Vascular Function**
  Session: Vascular/Diabetic Retinal Diseases: New Associations and Treatments
  Panel Date/Time: Thursday, December 3, 2026, 11:55 AM – 12:25 PM CET
  Panelist: Peter K. Kaiser, MD, Chief Development Officer

FLORetina 2026: December 3-6, 2026
Florence, Italy

- **Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) for Diabetic Retinopathy: Update on the HELIOS Program**
  Session: New Drugs & Clinical Trials
  Session Date/Time: Friday, December 4, 2026, 11:30 – 11:33 AM CET
  Presenter: Courtney Crawford, MD, FACS

- **Presentation: Evaluation of OTX-TKI for the Management of AMD: Key Insights from SOL-1**
  Session: US Retinal Therapies. Update from ASRS: Durable and Sustained Treatments for Neovascular AMD
  Session Date/Time: Friday, December 4, 2026, 3:57 – 4:01 PM CET
  Presenter: Jeffrey S. Heier, MD, Chief Scientific Officer

- **Symposium: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control**
  Symposium Date/Time: Saturday, December 5, 2026, 1:30 – 2:30 PM CET
  Faculty: Darius M. Moshfeghi, MD, FASRS; Adnan Tufail, MBBS, MD, FRCOphth; Anat Loewenstein, MD; Nadia K. Waheed, MD, MPH, Chief Medical Officer; Peter K. Kaiser, MD, Chief Development Officer

Exact medical conference presentation times and titles may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular's pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com